作者
Marek Jutel, Ioana Agache, Sergio Bonini, A Wesley Burks, Moises Calderon, Walter Canonica, Linda Cox, Pascal Demoly, Antony J Frew, Robin O'Hehir, Jörg Kleine-Tebbe, Antonella Muraro, Gideon Lack, Désirée Larenas, Michael Levin, Harald Nelson, Ruby Pawankar, Oliver Pfaar, Ronald Van Ree, Hugh Sampson, Alexandra F Santos, George Du Toit, Thomas Werfel, Roy Gerth van Wijk, Luo Zhang, Cezmi A Akdis
发表日期
2015/9/1
来源
Journal of Allergy and Clinical Immunology
卷号
136
期号
3
页码范围
556-568
出版商
Mosby
简介
Allergen immunotherapy (AIT) has been used to treat allergic disease since the early 1900s. Despite numerous clinical trials and meta-analyses proving AIT efficacious, it remains underused and is estimated to be used in less than 10% of patients with allergic rhinitis or asthma worldwide. In addition, there are large differences between regions, which are not only due to socioeconomic status. There is practically no controversy about the use of AIT in the treatment of allergic rhinitis and allergic asthma, but for atopic dermatitis or food allergy, the indications for AIT are not well defined. The elaboration of a wider consensus is of utmost importance because AIT is the only treatment that can change the course of allergic disease by preventing the development of asthma and new allergen sensitizations and by inducing allergen-specific immune tolerance. Safer and more effective AIT strategies are being continuously …
学术搜索中的文章
M Jutel, I Agache, S Bonini, AW Burks, M Calderon… - Journal of Allergy and Clinical Immunology, 2015